Case Study 1 — GHK-Cu: Real Science, and the Distance Between a Wound and a Face

Why this case

Most of the compounds this book rates ❌ are easy cases. There is a marketing claim, there is no human evidence, and the two are separated by a gap that anyone can see once it is pointed out.

GHK-Cu is not that. It is the hardest case in the cosmetic chapter, and it is hard in an instructive direction: the underlying laboratory science is genuinely good, genuinely old, and genuinely reproduced, and the consumer claim built on top of it is still not supported. Learning to hold both of those at once — without flattening either — is most of what evidence literacy consists of.

If you can work through this case honestly, you can work through almost anything in Part III.

The molecule and its history

GHK is a tripeptide: glycine, histidine, lysine. It occurs naturally in human plasma, from which it was first isolated in the early 1970s. Its defining chemical property is that it binds copper(II) with high affinity, forming the complex written GHK-Cu and appearing on cosmetic ingredient lists as copper tripeptide-1.

The copper is not decoration. Copper is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin into a matrix with mechanical integrity, and for one form of superoxide dismutase. A tissue rebuilding its extracellular matrix genuinely requires copper delivered to the right enzymes. A small peptide that binds copper tightly and hands it off is a coherent physiological proposition, and it is the reason the phrase "carrier peptide" exists as a category at all.

At roughly 340 daltons for the free tripeptide — with the copper complex not much heavier — GHK is also, unusually for this chapter, below the 500-dalton rule of thumb. Nearly every other cosmetic peptide fails that screen. This one passes it.

What the literature actually shows

Here is the part that must be stated plainly, because it is routinely misrepresented in both directions.

There is a substantial, decades-old body of work on GHK and GHK-Cu. It spans cell culture, animal wound models, and human wound contexts. Across that work, effects have been reported on collagen synthesis, on the behavior of fibroblasts and other cell types involved in repair, on aspects of extracellular matrix production, and on various markers of tissue remodeling. Papers have been appearing since the 1970s. The molecule has been studied by people with no commercial interest in skincare.

This is not fabricated science. Anyone who tells you copper peptides are "made up" has not read the literature and is doing the same thing as the marketer, only in the opposite direction — substituting a stance for a reading.

And now the gap.

Look at where the compelling results come from. Wound-healing models. Cell culture. Surgical and dermatological contexts in which tissue has been cut, burned, abraded, or otherwise opened.

In every one of those settings, the stratum corneum is already breached. The barrier that organizes all of Chapter 30 is simply not present, or not intact, at the site where the compound is applied. The molecule and the fibroblast are in the same room. Delivery — the question this chapter exists to ask — has been answered in advance by the injury.

Apply the same compound to intact facial skin and the question reopens completely. It is a different tissue state, a different exposure, and a different claim.

The structure of the inference

WHAT IS ESTABLISHED, AND WHERE IT STOPS

  ESTABLISHED (strong)     GHK-Cu affects fibroblast behavior and matrix
                           production in cell culture
        │
        │  requires: nothing. Cells are bathed directly in the compound.
        ▼
  ESTABLISHED (good)       GHK-Cu has effects in wound-healing models
        │
        │  requires: delivery to a WOUND — barrier already breached
        ▼
  ─────────── THE STRATUM CORNEUM GOES BACK UP HERE ───────────
        │
        │  requires: penetration of an INTACT barrier, at a
        │            therapeutically relevant concentration,
        │            from a cosmetic formulation
        ▼
  NOT ESTABLISHED          GHK-Cu applied to intact facial skin delivers a
                           relevant concentration to dermal fibroblasts
        │
        │  requires: all of the above, PLUS enough sustained matrix
        │            change to alter appearance
        ▼
  NOT ESTABLISHED          Topical GHK-Cu visibly rebuilds aging skin

  Notice: no step in this chain is fraudulent. Each step is a real inference
  someone made. The chain simply does not reach the bottom, and marketing
  quotes the top while claiming the bottom.

That diagram is the case study in one image. Nobody had to lie. The failure is entirely one of inference across a boundary — and the boundary is a physical object, about fifteen micrometers thick, sitting on your face.

Complications worth holding

Three, none of which change the rating but all of which change how confidently you should hold it.

GHK's size is a real advantage. It is not a rhetorical concession. Below 500 daltons, penetration is not ruled out on size grounds, and this compound therefore has a better prior than palmitoyl pentapeptide-4 or acetyl hexapeptide-8. What it lacks is the demonstration — a measurement of how much intact GHK-Cu reaches living human dermis from a cosmetic formulation. That measurement is achievable with current technology. Its absence, decades in, is itself mildly informative.

Copper is double-edged. The same redox activity that makes copper a useful enzyme cofactor makes free copper capable of generating reactive oxygen species, which is why tissue copper is tightly regulated. Complexed copper is not free copper, and cosmetic exposures are low — this is not a safety alarm. It is a caution about mechanism stories that are entirely upside. Real biology has trade-offs; marketing biology usually does not.

Formulation chemistry matters more here than almost anywhere else. The standard advice not to layer copper peptide products with vitamin C or acids is not mysticism: low pH and ascorbic acid can disrupt the copper complex. Which means a meaningful fraction of this compound's fate is decided in the bottle and on the bathroom shelf, before skin is involved at all.

The rating, and why it splits

📊 Evidence Rating

Claim: Topical GHK-Cu (copper tripeptide-1), applied to intact facial skin in healthy adults, improves the appearance of aging skin. Rating: ⚠️ for modest instrument-measured effects; ❌ for the strong marketing version. As of this writing, 2026. This is the rating given in Chapter 6 §6.8 and reproduced in Chapter 30 §30.4 — same claim, same answer. Why: A real, substantial, decades-old wound-healing and cell-culture literature; a molecule small enough that penetration is not ruled out; and human data on intact skin that is limited, small, short, largely industry-associated, and instrument-based. The strong claims extrapolate from a wound to a face. What would change it: For the ⚠️ — independently funded, vehicle-controlled trials on intact skin with blinded photographic endpoints over six months or more, plus demonstrated dermal delivery in living skin. For the ❌ — evidence that any measured change corresponds to a difference an observer notices.

The split is not fence-sitting. It is the rating system's rule 6 doing exactly what it is for: one molecule, many ratings, because "modest instrument-measured change" and "rebuilds collagen and reverses skin aging" are two different assertions with two different evidentiary requirements. The evidence meets one and not the other. Collapsing them into a single verdict destroys the only information a reader actually needs.

Discussion questions

1. Write the strongest possible case for topical GHK-Cu, using only true statements from this case study. Then identify the single sentence in your own case that does the most unearned work — the place where a real finding is quietly asked to cover a gap.

2. The chapter argues that a wound and intact skin are different settings for the same compound. Name two other places in this book where the same molecule earns different ratings because the tissue state or route differs, and say what those cases have in common with this one.

3. GHK is below the 500-dalton threshold, unlike most cosmetic peptides. Explain precisely what that fact establishes and what it does not. Then answer: if a study demonstrated tomorrow that GHK-Cu reaches the dermis at concentrations matching those used in cell culture, would that move the ⚠️, the ❌, both, or neither?

4. Someone argues: "Fifty years of research, hundreds of papers, effects reproduced in multiple laboratories — at some point the sheer weight of evidence should count for something." Respond. Take the argument seriously; it is not a stupid one. What kind of question does volume of evidence answer, and what kind does it not?

5. The mechanism story for GHK-Cu is entirely upside: copper is needed, the peptide delivers it, matrix improves. The case study flags this as a warning sign. Construct the version of the GHK-Cu mechanism story that a skeptical biologist would tell — one that includes the trade-offs — and say whether the more complicated version makes the compound more or less interesting to you.

6. You are writing consumer-facing copy for a copper peptide product, and you are constrained to say only what the evidence supports and to remain a cosmetic rather than a drug (§30.7). Write the front-of-box claim, in fewer than fifteen words. Then write the one-paragraph explanation you would put on the company's website. Finally, assess honestly: would your version sell?